Abstract
The p53 pathway is inactivated in essentially all human tumors p53 is lost or mutated in over 50% of all human cancers, and the majority of the remaining tumors carry mutations in other components of the pathway. It appears that the main biological function of p53 in vivo is to suppress tumorigenesis, because mice with homozygous deletion of the p53 gene are normal, but develop multiple tumors at an early age. p53 plays a central role in cell cycle control and apoptosis in response to DNA damage and other stresses, and in response to oncogenic activation. Loss of p53 function leads to excessive proliferation due to an inappropriate cell cycle control, or to a reduced apoptosis and an excess survival. This allows propagation of cells with damaged DNA resulting in increased genetic instability and enhanced risk of cancer. The contribution of each of the p53 functions, or the lack thereof, to tumor initiation and progression has been studied in vivo, in genetically modified mice. Mice with deletions of one or both p53 alleles have been crossed with mice expressing dominant oncogenes, or lacking other tumor suppressor genes, in order to analyse the genetic interaction between different tumorigenic pathways in vivo. These studies have defined how oncogenic mutations can cooperate in tumorigenesis in tissue and the tumor-specific ways.
Keywords: tumor suppression, oncogene, tumorigenesis
Current Genomics
Title: Studies of p53 Tumor Suppression Activity in Mouse Models
Volume: 3 Issue: 4
Author(s): Dionisio Martin-Zanca
Affiliation:
Keywords: tumor suppression, oncogene, tumorigenesis
Abstract: The p53 pathway is inactivated in essentially all human tumors p53 is lost or mutated in over 50% of all human cancers, and the majority of the remaining tumors carry mutations in other components of the pathway. It appears that the main biological function of p53 in vivo is to suppress tumorigenesis, because mice with homozygous deletion of the p53 gene are normal, but develop multiple tumors at an early age. p53 plays a central role in cell cycle control and apoptosis in response to DNA damage and other stresses, and in response to oncogenic activation. Loss of p53 function leads to excessive proliferation due to an inappropriate cell cycle control, or to a reduced apoptosis and an excess survival. This allows propagation of cells with damaged DNA resulting in increased genetic instability and enhanced risk of cancer. The contribution of each of the p53 functions, or the lack thereof, to tumor initiation and progression has been studied in vivo, in genetically modified mice. Mice with deletions of one or both p53 alleles have been crossed with mice expressing dominant oncogenes, or lacking other tumor suppressor genes, in order to analyse the genetic interaction between different tumorigenic pathways in vivo. These studies have defined how oncogenic mutations can cooperate in tumorigenesis in tissue and the tumor-specific ways.
Export Options
About this article
Cite this article as:
Martin-Zanca Dionisio, Studies of p53 Tumor Suppression Activity in Mouse Models, Current Genomics 2002; 3 (4) . https://dx.doi.org/10.2174/1389202023350336
DOI https://dx.doi.org/10.2174/1389202023350336 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |
Call for Papers in Thematic Issues
Advanced AI Techniques in Big Genomic Data Analysis
The thematic issue on "Advanced AI Techniques in Big Genomic Data Analysis" aims to explore the cutting-edge methodologies and applications of artificial intelligence (AI) in the realm of genomic research, where vast amounts of data pose both challenges and opportunities. This issue will cover a broad spectrum of AI-driven strategies, ...read more
Current Genomics in Cardiovascular Research
Cardiovascular diseases are the main cause of death in the world, in recent years we have had important advances in the interaction between cardiovascular disease and genomics. In this Research Topic, we intend for researchers to present their results with a focus on basic, translational and clinical investigations associated with ...read more
Deep learning in Single Cell Analysis
The field of biology is undergoing a revolution in our ability to study individual cells at the molecular level, and to integrate data from multiple sources and modalities. This has been made possible by advances in technologies for single-cell sequencing, multi-omics profiling, spatial transcriptomics, and high-throughput imaging, as well as ...read more
Genomic Insights into Oncology: Harnessing Machine Learning for Breakthroughs in Cancer Genomics.
This special issue aims to explore the cutting-edge intersection of genomics and oncology, with a strong emphasis on original data and experimental validation. While maintaining the focus on how machine learning and advanced data analysis techniques are revolutionizing our understanding and treatment of cancer, this issue will prioritize contributions that ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Metastasis Suppressors: Basic and Translational Advances
Current Pharmaceutical Biotechnology Bisphosphonates: Molecular Mechanisms of Action and Effects on Bone Cells, Monocytes and Macrophages
Current Pharmaceutical Design Sch-66336 (Sarasar®) and Other Benzocycloheptapyridyl Farnesyl Protein Transferase Inhibitors: Discovery, Biology and Clinical Observations
Current Topics in Medicinal Chemistry Determinants of Anti-Cancer Effect of Mitochondrial Electron Transport Chain Inhibitors: Bioenergetic Profile and Metabolic Flexibility of Cancer Cells
Current Pharmaceutical Design Design and Synthesis of Novel Thioethers Derived from 1,5-Diphenyl-6- thioxo-6,7-dihydro-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-ones as Antiangiogenic Agents
Letters in Drug Design & Discovery The Role of Epigenetics in Drug Resistance in Cancer
Epigenetic Diagnosis & Therapy (Discontinued) Insulin-like Growth Factor: Current Concepts and New Developments in Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery New Strategies in the Chemotherapy of Leukemia: Eradicating Cancer Stem Cells in Chronic Myeloid Leukemia
Current Cancer Drug Targets Tubulin Maytansine Site Binding Ligands and their Applications as MTAs and ADCs for Cancer Therapy
Current Medicinal Chemistry Harnessing Phage Display for the Discovery of Peptide-Based Drugs and Monoclonal Antibodies
Current Medicinal Chemistry Panobinostat: The Small Molecule Metalloenzyme Inhibitor with Marvelous Anticancer Activity
Current Topics in Medicinal Chemistry High Therapeutic Potential for Systemic Delivery of a Liposomeconjugated Herpes Simplex Virus
Current Cancer Drug Targets Design, Synthesis and In-Vitro Cytotoxicity of Novel Platinum (II) Complexes with Phthalate as the Leaving Group
Letters in Drug Design & Discovery Hypericin - The Facts About a Controversial Agent
Current Pharmaceutical Design Editorial (Thematic Issue: Novel Pharmaceutical Approaches by Natural Compound-Derived Epigenetic Regulators: Epigenetic Readers, Writers and Erasers as Therapeutic Targets)
Current Topics in Medicinal Chemistry Bacteria and Bacterial Toxins as Therapeutic Agents for Solid Tumors
Current Cancer Drug Targets Multifunctional Materials for Cancer Therapy: From Antitumoral Agents to Innovative Administration
Current Organic Chemistry Updated Review and Perspective on 20S Proteasome Inhibitors in the Treatment of Lung Cancer
Current Cancer Drug Targets Role of Pemetrexed and Platinums Combination in Patients with Non- Small Cell Lung Cancer
Current Drug Targets Current Status and Future Perspectives on Old Drug Repurposing for Cancer Treatment
Recent Patents on Anti-Cancer Drug Discovery